Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15Prostatic Neoplasms, Castration-Resistant 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Penile Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × niraparib × Genitourinary × Clear all
NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Janssen Research & Development, LLC

Approved for marketing
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡